A large purity percentage can look like a complete quality verdict. It is not. Before interpreting an analytical report, separate the questions being asked: what molecule was detected, what else was detected, how much material was present, and which microbiological properties were examined. A result only answers the question its method was designed and validated to answer.
This article explains what analytical methods measure and how to read their results. The regulatory documents cited here describe measurement principles within defined scopes; they do not certify any particular sample.
Five questions that need separate evidence
| Question | What the result addresses |
|---|---|
| Identity | Whether the measured material matches the proposed molecular identity. |
| Purity | The relative presence of target material and detectable impurities under specified methods. |
| Content | The quantity or mass fraction of peptide, on a defined measurement basis. |
| Sterility | Evidence concerning viable microorganisms, within a test and process-control framework. |
| Endotoxin | A distinct bacterial contaminant measured with an appropriate assay. |
ICH Q6B distinguishes identity, purity, quantity and other specifications for biological products, rather than treating them as interchangeable. The guidance has a defined regulatory scope, which matters when applying its framework to other materials. ICH specification framework.
What an HPLC percentage leaves out
High-performance liquid chromatography separates components under particular conditions. When purity is reported as a proportion of detected peak area, the denominator is the material the method detects and resolves—not automatically the entire weighed sample. Components that overlap, respond differently or are not measured can complicate interpretation.
Merck’s technical explanation makes a concrete distinction: peptide purity measured using ultraviolet detection does not account for water and salts in the sample. Peptide content is a separate measurement. Therefore, a high HPLC purity result cannot by itself verify the net peptide amount printed on a vial. Read the method and the reporting basis before comparing two percentages. Manufacturer’s explanation of purity and content.
Mass spectrometry supports identity, within its limits
A mass spectrum adds molecular information that a chromatogram alone cannot supply. Agreement with an expected molecular mass is useful evidence, but a complete identity assessment can require peptide mapping, sequence information and complementary techniques. The analytical question determines how much evidence is sufficient. ICH Q6B describes multiple structural-characterisation approaches, including mass spectrometry, rather than a single universal identity test. Structural characterisation guidance.
Quantity also deserves its own evidence. A metrology study using angiotensin I examined different approaches to assigning peptide purity, including mass balance, amino-acid analysis and quantitative nuclear magnetic resonance. That work concerns traceable measurement; it does not suggest that a chromatographic percentage alone settles every content question. NIST’s peptide value-assignment study.
A method name is not a validation record
Seeing “HPLC” or “LC-MS” on a report tells you the general technique, not whether it can answer the specific question reliably. Relevant validation characteristics include selectivity, accuracy, precision and an appropriate measurement range. Detection and quantitation limits matter when interpreting a report that says an impurity was not detected.
“Not detected” is conditional on the method’s capability; it is not a mathematical claim that no molecules of an impurity exist. ICH Q2(R2), whose current EMA version was updated in February 2026, provides a framework for evaluating analytical performance. Current analytical-validation guideline.
Sterility and endotoxin are different questions
Sterility cannot be inferred from a clear solution, a sealed container or a chemical-purity result. FDA’s manufacturing guidance explains that finished-product sterility testing has limitations and belongs within a wider system of manufacturing controls. A tested sample is not the same thing as direct observation of every unit in a batch. FDA discussion of sterility assurance, question 22.
Endotoxin is another question again: bacterial components can remain even when viable organisms are absent. FDA’s historical technical discussion documents why sterile products can still contain endotoxin; its older test limits should not be treated as current specifications. Background on endotoxin and sterility. For current testing considerations, the agency issued revised guidance in March 2026. An endotoxin result needs its own method, units and relevant acceptance criteria; it cannot be substituted with an HPLC percentage. FDA’s 2026 testing guidance.
Read the document as evidence, not decoration
A practical document review starts with the sample identifier, lot linkage, testing date, laboratory, methods, results and units. Check whether the report actually addresses the property being claimed. Ask for clarification when a claim outruns the supplied evidence; do not fill a missing test with an assumption.
That distinction protects research interpretation. An analytical result may support a particular sample measurement while leaving quantity, stability or microbiological status unresolved. Record those unknowns explicitly. Neither polished packaging nor a familiar instrument name closes an evidence gap.
Continue with How to read a clinical trial for a closer look at interpreting research evidence.
Sources and further reading
- Peptide purity and content explained — Primary manufacturer technical documentation; Accessed 2026-10-31.
- ICH Q6B: biological-product specifications — Primary regulatory guideline; 1999-09.
- NIST peptide purity value-assignment study — Primary research publication record; 2018-03-27.
- ICH Q2(R2): analytical validation — Primary regulatory guideline; 2026-02-20.
- FDA production-control guidance, question 22 — Primary agency guidance; 2023-08-11.
- FDA background on bacterial endotoxins — Primary historical agency technical guidance; 1985-03-20.
- FDA's revised pyrogen and endotoxin guidance — Primary agency guidance; 2026-03.
